Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies, has closed a $15 million Series A financing. The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors.

Kurome Therapeutics is a preclinical stage company developing novel therapies that subvert cancer's ability to evade treatment. Founded on research at Cincinnati Children's Hospital Medical Center in collaboration with the National Institutes of Health's National Center for Advancing Translational Sciences (NCATS), Kurome is developing a series of combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that have co-opted IRAK1/4-mediated immune signaling pathways to survive.